AC Immune (ACIU) Receivables (2014 - 2026)
AC Immune (ACIU) posted quarterly Receivables of $1.3 million for Q4 2024, down 99.99% year-over-year from $16.7 billion in Q1 2024, and down 95.71% quarter-over-quarter from $29.4 million in Q3 2024.
AC Immune (ACIU) Receivables (2014 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Receivables for 10 consecutive years, with $1.3 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Receivables fell 99.99% year-over-year to $1.3 million; the TTM figure through Dec 2024 stood at $1.3 million (down 99.99% YoY), while the FY2024 annual figure was $1.3 million, down 99.99% from the prior year.
- Receivables fell to $1.3 million in Q4 2024 per ACIU's latest filing, from $29.4 million in the prior quarter.
- Across five years, Receivables topped out at $16.7 billion in Q4 2023 and bottomed at $1.3 million in Q4 2024.
- Historically, Receivables has averaged $2.5 billion across 4 years, with a median of $62.6 million in 2020.
- Annual changes were most pronounced in 2021 — Receivables surged 610.64% — and 2024, when it plunged 99.99%.
- AC Immune's Receivables stood at $66.4 million in 2020, then soared by 610.64% to $471.6 million in 2021, then soared by 3437.7% to $16.7 billion in 2023, then slumped by 99.99% to $1.3 million in 2024.
- Business Quant data shows ACIU's Receivables at $1.3 million in Q4 2024, $29.4 million in Q3 2024, and $1.3 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 17.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.00 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 29.40 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Dec 31, 2023 | 16.69 Bn |
| Dec 31, 2021 | 471.65 Mn |
| Dec 31, 2020 | 66.37 Mn |
| Mar 31, 2020 | 62.60 Mn |
| Dec 31, 2019 | 307.46 Mn |
| Sep 30, 2019 | 33.45 Mn |
| Mar 31, 2019 | 30.91 Mn |
| Dec 31, 2018 | 254,223.20 |
| Dec 31, 2017 | 1.63 Mn |
| Dec 31, 2016 | 699,017.08 |
| Dec 31, 2015 | 26.21 Mn |
| Dec 31, 2014 | -26.64 Mn |